Fig. 3

Pharmacological inhibition of thioredoxin confers BTZ-resistant myeloma cells growth arrest both in vitro and in vivo. a Cell viability of MM.1R-BTZ-resistant cells following 48 h of PX12 treatment. b Effect of PX12 on MM.1R-BTZ-resistant cells following 48 h of BTZ co-treatment. c Cell viability of RPMI8226/Dox-BTZ-resistant cells following 48 h of PX12 treatment. d Effect of PX12 on RPMI8226/Dox-BTZ-resistant cells following 48 h of BTZ co-treatment. e Tumor growth curves of the subcutaneous xenograft tumor model with MM.1R-cells treated with control buffer, BTZ alone, PX12 alone or the combination of BTZ and PX12. f Representative images of MM.1R-BTZ-resistant tumor dissected from sacrificed mice are shown in this panel. g Tumor weight in mice xenograft with MM.1R-BTZ-resistant cells treated with control buffer, BTZ alone, PX12 alone, or the combination of BTZ and PX12. For this experiment, mice were treated with either BTZ (0.5 mg/kg, twice weekly, i.p.), PX12 (12 mg/kg, twice weekly, i.p.) or the combination. Error bars, standard error of the mean (SEM); *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001